首页>Viral immunology>Enhanced Immunity and Protective Efficacy against SIV(mac251) Intrarectal Challenge Following Ad-SIV Priming by Multiple Mucosal Routes and gp120 Boosting in MPL-SE.
Enhanced Immunity and Protective Efficacy against SIV(mac251) Intrarectal Challenge Following Ad-SIV Priming by Multiple Mucosal Routes and gp120 Boosting in MPL-SE.
作者单位:Vaccine Branch, National Cancer Institute, Bethesda, MD 20892., Present address: Institute of Human Virology, University of Maryland, Baltimore, MD 21201.[1]